Merck has struck a deal worth up to $1.3 billion to buy an investigational drug targeting B-cell associated diseases.
Related Posts
Starbucks’s New Boss Gets an Unusual Perk: Remote Work
Brian Niccol will be able to live in his home in Southern California and commute to Starbucks’s head office on a corporate jet.
Decision Time for GM in China: Stay, Scale Back or Go
The country’s sharp shift to EVs and stronger local competition have deflated a key profit engine for the U.S. automaker.
Elon Musk Plays a Familiar Song: Robot Cars Are Coming
Tesla’s Robotaxi event excites the faithful betting on the company’s future in robotics, while underwhelming those watching from afar.